Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen.
Looking at options history for Amgen AMGN we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $232,384 and 6, calls, for a total amount of $241,377.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $340.0 for Amgen over the last 3 months.
Insights into Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $280.0 to $340.0 in the last 30 days.
Amgen Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $5.3 | $4.7 | $4.7 | $330.00 | $133.9K | 462 | 330 |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $24.45 | $23.55 | $24.35 | $340.00 | $61.0K | 1.2K | 51 |
| AMGN | CALL | TRADE | BEARISH | 10/18/24 | $60.35 | $58.75 | $58.75 | $280.00 | $41.1K | 82 | 7 |
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $27.45 | $26.6 | $26.6 | $330.00 | $39.9K | 1.1K | 1 |
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $26.75 | $26.35 | $26.35 | $330.00 | $39.5K | 1.1K | 43 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Amgen Standing Right Now?
- With a trading volume of 158,874, the price of AMGN is down by -0.24%, reaching $336.58.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 36 days from now.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
